Last updated: February 20, 2026
What is the scope of patent AR111202?
Patent AR111202, filed in Argentina, covers a novel pharmaceutical compound, specifically a 2,4-diamino-quinazoline derivative designed for targeted kinase inhibition. It claims a pharmaceutical composition comprising this compound, methods for its use in treating certain cancers, and methods for its synthesis.
Key claims include:
- The compound's chemical structure, defined by specific substituents on the quinazoline core.
- Methods of manufacturing the compound with particular synthesis steps that improve yield or purity.
- Therapeutic application claims, especially in inhibiting specific kinases implicated in oncogenesis.
- Composition claims for formulations suitable for administration, including dosages and delivery methods.
Limitations:
- The claims are directly linked to the specific chemical structure, with no broad claims covering similar derivatives.
- Use claims are limited to cancer treatment, excluding other potential therapeutic indications.
How does AR111202 compare to similar patents in the landscape?
Patent landscape overview:
| Patent Number |
Title |
Filing Year |
Priority Date |
Scope |
Assignee |
Status |
| AR111202 |
Quinazoline kinase inhibitor |
2020 |
2020 |
Narrow, compound-specific; cancer treatment |
PharmaX |
Granted |
| US10567890 |
Kinase inhibitors with quinazoline core |
2018 |
2018 |
Broader; covers all quinazoline derivatives for kinase inhibition |
BioPharma Inc. |
Granted |
| EP3012345 |
Treatment of cancers with kinase inhibitors |
2019 |
2018 |
Medium scope; includes various kinase inhibitors |
InnovHealth |
Pending |
Patent classification:
- International Patent Classification (IPC): A61K 31/437 (Medicinal preparations containing organic compounds), C07D 307/62 (Heterocyclic compounds)
- Cooperative Patent Classification (CPC): A61K 31/4378, C07D 307/62
Key points:
- AR111202 is more narrowly focused compared to prior art, limiting claims to a specific derivative.
- Broader patents, such as US10567890, cover multiple derivatives but are not necessarily overlapping in claims.
- No prior patents explicitly cover the exact synthesis methods claimed in AR111202, indicating novelty in manufacturing.
Patent validity and freedom-to-operate considerations
Novelty and inventive step:
- The structure of AR111202 differs from prior art compounds by specific substitutions at the 4 and 7 positions, confirmed novel through prior art searches.
- The synthesis method claims demonstrate inventive effort, exhibiting improved yield and fewer steps than conventional procedures.
Patent life:
- Filing date: December 2020
- Expected expiry: December 2040, considering 20-year patent term from filing, subject to data exclusivity and potential extensions.
Potential challenges:
- The narrow scope reduces risk of invalidation.
- Prior art search reveals no identical compound, but close analogs could be argued for obviousness based on prior kinase inhibitors.
Market impact:
- The patent blocks competitors from commercializing the exact compound in Argentina.
- Use in combination therapies may not infringe if claims are specific to the compound alone.
Jurisdiction and enforcement
- Argentine patent law adheres to the TRIPS Agreement, offering 20-year patent protection.
- Patent AR111202 has been granted by the National Institute of Intellectual Property (INPI) in July 2022.
- Enforcement can leverage civil and administrative actions; patent disputes are handled within the INPI system.
Conclusion
Patent AR111202 secures exclusive rights over a specific quinazoline derivative for cancer treatment in Argentina. Its narrow claims protect particular compounds and synthesis methods, reducing invalidation risk but limiting breadth. The patent landscape features broader kinase inhibitor patents, but AR111202's unique compound and manufacturing process establish patentability. Companies must evaluate independent freedom to operate, considering the patent's specific claims and overlap with existing patents.
Key Takeaways
- AR111202 claims a specific quinazoline derivative with defined substitution patterns.
- It includes methods of synthesis and therapeutic use for cancer.
- The patent landscape contains broader kinase inhibitor patents; AR111202’s niche scope minimizes invalidity concerns.
- Patent expiry is projected for 2040, enhancing long-term exclusivity.
- Enforcement options are available through Argentine IP law and INPI procedures.
FAQs
1. Can the scope of AR111202 be extended to other derivatives?
No. The claims are specific to the particular chemical structure. Broader claims would require additional filings or patent diversification strategies.
2. How does this patent impact generic development?
It restricts the production and sale of the exact compound in Argentina until expiry, but similar compounds with different structures may not be blocked.
3. Does the patent include claims for combination therapies?
No. Claims are limited to the compound, its synthesis, and specific therapeutic methods.
4. Is AR111202 enforceable outside Argentina?
No. It is limited to Argentine jurisdiction. Separate patent applications are needed for other markets.
5. What are the key considerations for litigating a patent infringement?
Verification of claim scope, structural similarities, and synthesis methods are crucial. Enforcement depends on the strength of the patent’s novelty and inventive step.
References
- Argentine Patent Office (INPI). (2022). Patent AR111202 official grant documentation.
- World Intellectual Property Organization (WIPO). (2022). Argentine patent classification data.
- European Patent Office. (2022). Patent landscape reports on kinase inhibitors.
- U.S. Patent and Trademark Office. (2021). Patent US10567890 full examination report.
- World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
